Malcolm R Macleod
Overview
Explore the profile of Malcolm R Macleod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
8237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bannach-Brown A, Rackoll T, Macleod M, McCann S
BMC Med Res Methodol
. 2025 Mar;
25(1):66.
PMID: 40065205
In this review article, we provide a comprehensive overview of current practices and challenges associated with research synthesis in preclinical biomedical research. We identify critical barriers and roadblocks that impede...
2.
Siafis S, Nomura N, Schneider-Thoma J, Bighelli I, Bannach-Brown A, Ramage F, et al.
F1000Res
. 2025 Jan;
13:1017.
PMID: 39844929
Background: Muscarinic receptor agonism and positive allosteric modulation is a promising mechanism of action for treating psychosis, not present in most D2R-blocking antipsychotics. Xanomeline, an M1/M4-preferring agonist, has shown efficacy...
3.
Pal S, Chataway J, Swingler R, Macleod M, Carragher N, Hardingham G, et al.
Lancet Neurol
. 2024 Sep;
23(11):1097-1107.
PMID: 39307154
Background: Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of...
4.
Siafis S, Chiocchia V, Macleod M, Austin C, Homiar A, Tinsdeall F, et al.
Wellcome Open Res
. 2024 Jul;
9:182.
PMID: 39036710
Background: Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods: We co-produced a living systematic review of...
5.
Hair K, Wilson E, Maksym O, Macleod M, Sena E
J Neurosci Methods
. 2024 Jul;
409:110209.
PMID: 38964475
Background: Despite extensive investment, the development of effective treatments for Alzheimer's disease (AD) has been largely unsuccessful. To improve translation, it is crucial to ensure the quality and reproducibility of...
6.
Ineichen B, Furrer E, Gruninger S, Zurrer W, Macleod M
PLoS Biol
. 2024 Jun;
22(6):e3002667.
PMID: 38870090
There is an ongoing debate about the value of animal experiments to inform medical practice, yet there are limited data on how well therapies developed in animal studies translate to...
7.
Siafis S, McCutcheon R, Chiocchia V, Ostinelli E, Wright S, Stansfield C, et al.
Wellcome Open Res
. 2024 Apr;
8:365.
PMID: 38634067
Background: There is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct...
8.
Weissgerber T, Gazda M, Nilsonne G, Ter Riet G, Cobey K, Priess-Buchheit J, et al.
Nat Med
. 2024 Mar;
30(5):1220-1221.
PMID: 38514869
No abstract available.
9.
de Jonge J, Sluis W, Reinink H, Bath P, Woodhouse L, Zweedijk B, et al.
Lancet Reg Health Eur
. 2023 Dec;
36:100782.
PMID: 38074444
Background: Infections and fever after stroke are associated with poor functional outcome or death. We assessed whether prophylactic treatment with anti-emetic, antibiotic, or antipyretic medication would improve functional outcome in...
10.
Ineichen B, Rosso M, Macleod M
Lab Anim (NY)
. 2023 Sep;
52(10):213-214.
PMID: 37758917
No abstract available.